Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 24Neoplasms 10Fallopian Tube Neoplasms 7Breast Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 3Neoplasm Metastasis 2Mesothelioma 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Neoplasms 1Urothelial Cancer 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma, Ewing 1Recurrence 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Pancreatic Adenocarcinoma 1Ovarian Diseases 1Mesothelioma, Malignant 1Melanoma 1Leukemia, Prolymphocytic, T-Cell 1

Interventions

niraparib 1abemaciclib 1Radiotherapy 1Mastectomy, Segmental 1Mastectomy 1Continuous Positive Airway Pressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Unilateral Breast Neoplasms × niraparib × Clear all
NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

OHSU Knight Cancer Institute

Phase 1 Completed
8 enrolled
Breast

Unilateral Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡